RxDoctor Payments Data

Mary Seegars, MD

Hematology & Oncology · Winston Salem, NCNPI 1184064073

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $829 of the $1,013 with a category attached, or 81.8%. 8 manufacturers reported payments, led by Gilead at 29.7% of the total. That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.

$1,013in general payments, 2019–2025

Across 12 payments — averaging $84.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$301
  • Genentech USA, Inc.$184
  • Adaptive Biotechnologies Corporation$157
  • Jazz Pharmaceuticals Inc.$100
  • Novartis$91
  • E.r. Squibb & Sons, L.L.C.$90
  • plus $91 from 2 others
$759,545in research payments, 2019–2025

Across 35 payments — averaging $21,701 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$617K
  • Pfizer$74K
  • Seagen Inc.$69K

What the payments were for

  • Food & beverage$82982%
  • Education$18418%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,013 in reported general payments places this provider in the 40th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,414
Medicare patients
129
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib12$178,010
GleevecImatinib Mesylate12$124,506
MethotrexateMethotrexate Sodium11$246
Dexamethasone25$211
Acyclovir20$199
Ondansetron Hcl17$68
Pantoprazole Sodium12$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisGleevec$91$124,50612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →